| scholarly article | Q13442814 |
| P50 | author | Kyun-Seop Bae | Q58660629 |
| Choung-Soo Kim | Q56635696 | ||
| P2093 | author name string | Jeongbeob Seo | |
| Je-Hwan Lee | |||
| Jene Choi | |||
| Jung Jin Hwang | |||
| Bon-Kwan Goo | |||
| Eun-Hye Hur | |||
| Yunsuk Choi | |||
| Juhyun Moon | |||
| Gilnam Lee | |||
| Sang-Hwa Yang | |||
| Suk Young Cho | |||
| P2860 | cites work | Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia | Q24299821 |
| ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF | Q24304344 | ||
| Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms | Q24554353 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | Q27851698 | ||
| beta-catenin signaling and cancer | Q28139147 | ||
| ITF-2 is disrupted via allelic loss of chromosome 18q21, and ITF-2B expression is lost at the adenoma-carcinoma transition | Q28242735 | ||
| Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo | Q28298865 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 | ||
| The NCI60 human tumour cell line anticancer drug screen | Q29614975 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression | Q30498959 | ||
| Serotonin activates the mitogen-activated protein kinase pathway in vascular smooth muscle: use of the mitogen-activated protein kinase kinase inhibitor PD098059 | Q71901120 | ||
| MEK and the inhibitors: from bench to bedside | Q34036341 | ||
| Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines | Q34129528 | ||
| Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells | Q34356765 | ||
| Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress | Q34528331 | ||
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Q34531564 | ||
| A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. | Q34768386 | ||
| Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis | Q35025086 | ||
| Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens | Q35126758 | ||
| Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas | Q35788961 | ||
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models | Q35835097 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 | Q36083385 | ||
| The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions | Q36360691 | ||
| Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer | Q36394050 | ||
| Bioinformatics approaches in the study of cancer | Q36740530 | ||
| CpG methylation in exon 1 of transcription factor 4 increases with age in normal gastric mucosa and is associated with gene silencing in intestinal-type gastric cancers | Q36838033 | ||
| Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | Q37596249 | ||
| Molecular Markers of Response to Treatment for Melanoma | Q37856122 | ||
| MEK inhibitors as a chemotherapeutic intervention in multiple myeloma | Q38092584 | ||
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | Q38300326 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance | Q39227285 | ||
| Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. | Q39254701 | ||
| Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice | Q39333811 | ||
| The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor | Q39353140 | ||
| KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer | Q39860040 | ||
| AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. | Q40079285 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| CpG methylation of transcription factor 4 in gastric carcinoma | Q43002651 | ||
| Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. | Q45957588 | ||
| Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | Q46441674 | ||
| Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. | Q46615053 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation | Q53389043 | ||
| Overcoming resistance to MAPK pathway inhibitors. | Q54464748 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 41387-41400 | |
| P577 | publication date | 2017-05-15 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells | |
| P478 | volume | 8 |
| Q89873581 | Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia | cites work | P2860 |
Search more.